Inveltys
Product Images NDC 71571-121

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Inveltys (NDC 71571-121). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alcon Laboratories, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Inveltys 01)

Chemical structure diagram of the active ingredient in Inveltys, showing the molecular arrangement with carbon rings, hydroxyl, chloro, and ester functional groups. The structure includes multiple chiral centers and side chains characteristic of the corticosteroid molecule.*

FDA Label Image

Figure 1 (Inveltys 02)

A bar chart showing the percent of patients with complete resolution of anterior chamber cells over two time points, Day 8 and Day 15. The chart compares results for Inveltys BID (n=386) and vehicle (n=385), with Inveltys showing higher percentages at both days (24% vs. 13% on Day 8 and 50% vs. 27% on Day 15).*

FDA Label Image

Figure 2 (Inveltys 03)

A bar chart comparing the percent of patients with complete resolution of pain (Grade = 0) over days 4, 8, and 15 between Inveltys BID (n=386) and Vehicle (n=385). The chart shows higher percentages for Inveltys BID at each time point (43%, 56%, 69%) compared to Vehicle (25%, 36%, 48%), with statistical significance indicated by asterisks above the Inveltys bars.*

FDA Label Image

Principal Display Panel (2.8 mL Bottle Carton)

Packaging label for Inveltys (loteprednol etabonate ophthalmic suspension) 1%, 2.8 mL sterile bottle. The label includes directions for topical eye application, storage instructions to keep the product upright at 15° to 25°C, and warnings against freezing or using if the tamper-evident overcap is missing. The product is manufactured for Kala Pharmaceuticals, Inc., with their logo and patent information. The label also displays the NDC 71571-121-28 and barcode.*

FDA Label Image

Inveltys 05

Instructional illustration showing a step-by-step visual guide for using an Inveltys eye drop bottle. The first image shows the closed bottle, the second shows the cap being twisted open, and the third shows the cap being disposed into a trash bin.*

FDA Label Image

Inveltys 06

Inveltys ophthalmic suspension bottle with a white base and a pink cap, showing text that includes the proprietary name Inveltys and the active ingredient loteprednol etabonate. The image illustrates the bottle design, including a depiction of the cap's range of motion. The labeler is Alcon Laboratories, Inc.*

FDA Label Image

Inveltys 07

Illustration showing how to remove the cap from an Inveltys ophthalmic suspension bottle. The image shows the Inveltys bottle with the cap being twisted off, exposing the dropper tip. The label on the bottle reads Inveltys, indicated as the product by ALCON LABORATORIES, INC.*

FDA Label Image

Inveltys 08

Illustration of an Inveltys eye drop bottle dispensing a single drop. The bottle is labeled with the brand name Inveltys and shows a drop falling from the nozzle, indicating usage as an ophthalmic solution.*

FDA Label Image

Inveltys 09

A black-and-white line drawing showing a person applying eye drops. The illustration depicts a hand holding an eye drop bottle above the open eye, with the other hand supporting the face below the eye.*

FDA Label Image

Inveltys 10

An instructional illustration showing two views of an Inveltys bottle with a pink cap. The left side includes an arrow indicating the cap should be twisted to open or close the bottle. The right side shows the bottle with the cap fully closed.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.